South Dakota Medicaid spending on GLP-1 drugs

How much did South Dakota Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $15.7 million for GLP-1 drugs paid through South Dakota Medicaid in 2025, across at least 15,602 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 40 rows of 113, so these figures are floors.

Pharmacies were reimbursed at least $4.1 million for GLP-1 drugs paid through South Dakota Medicaid in 2026 (quarter 1 only, as posted so far), across at least 3,936 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 17 rows of 34, so these figures are floors.

By year and ingredient

2020at least $469,936No data$364,671at least $601,879at least $190,062$56,409Suppressedat least $1,682,957
2021at least $1,151,258No data$306,176at least $832,465at least $209,191$71,697Suppressedat least $2,570,787
2022at least $2,413,649at least $41,121$287,978at least $888,732at least $132,055$48,497Suppressedat least $3,812,031
2023at least $3,757,685at least $1,134,214$217,973$802,111at least $57,721at least $26,477Suppressedat least $5,996,182
2024at least $6,290,794at least $4,215,857at least $159,609$723,541$45,996$53,016Suppressedat least $11,488,813
2025at least $7,040,697at least $7,848,232at least $46,638$719,820Suppressed$54,460Suppressedat least $15,709,847
2026 (Q1)at least $1,522,435at least $2,439,627Suppressed$154,065No dataSuppressedSuppressedat least $4,116,128

By product, 2025

Ozempicat least $6,630,757at least 6,7871 of 13
Rybelsus$409,9394230 of 12
WegovySuppressedSuppressed12 of 12
Mounjaroat least $7,848,232at least 7,4863 of 27
Liraglutide (generic name listing)at least $46,638at least 8216 of 21
VictozaSuppressedSuppressed2 of 2
Trulicity$719,8207430 of 16
BydureonSuppressedSuppressed2 of 2
Soliqua$54,460810 of 4
XultophySuppressedSuppressed4 of 4

By quarter, 2025

Q1 2025at least $3,720,471at least 3,7237 of 26
Q2 2025at least $3,827,419at least 3,8188 of 27
Q3 2025at least $3,928,138at least 3,89312 of 29
Q4 2025at least $4,233,819at least 4,16813 of 31

By quarter, 2026 (posted so far)

Q1 2026at least $4,116,128at least 3,93617 of 34

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.